Purchase this article with an account.
Rocio Blanco-Garavito, Hassiba Oubraham, Benjamin Wolff, Salomon Y Cohen, Catherine P Garcher, Jean-Francois Korobelnik, Christian Delhay, Ramin Tadayoni, Audrey Derveloy, Eric H Souied, French LUMINOUS Group.; Baseline characteristics of French patients with wet age-related macular degeneration(wAMD) enrolled in the LUMINOUS study.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5364. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the baseline characteristics of the French enrolled wAMD patients in the LUMINOUS (NCT01318941) study.
LUMINOUS is an ongoing, global, 5-year multicenter, prospective, observational study to evaluate the long-term safety, effectiveness, treatment patterns and health-related quality-of-life associated with ranibizumab (RBZ) treatment in clinical practice for all licensed indications. Interim data are available for a total of 17,545 adult wAMD patients globally. We analyzed the baseline characteristics of the 469 wAMD patients enrolled in France prior to March 2014.
In the French wAMD cohort, 16 (3.4%) patients were treatment naïve (T1), 452 (96.4%) had received prior ranibizumab treatment (T2), and 1 (0.2%) had previously received other ocular treatments for wAMD. The baseline characteristics of the French/global wAMD cohorts were: mean age 79.0/77.4 years and 32.4/42.0% were male. For the French/global wAMD cohorts, mean baseline visual acuity (VA, Early Treatment Diabetic Retinopathy Study [ETDRS] letter score) was 49.4/48.8 for T1 and 58.9/56.4 for T2; 68.9/42.4% had Pigment Epithelium Detachment (PED). Non-ocular comorbidities for the French/global wAMD patients included myocardial infarction (5.5/7.3%), stroke (5.5/5.6%), other thromboembolic events (4.9/4.9%), family history of coronary artery disease (14.1/14.9%), diabetes (10.7/14.5%), hypertension (51.4/56.7%), and obesity (BMI >30kg/m2; 11.5/10.0%). For those having received prior ranibizumab treatment, the mean duration of treatment was 2.5 years and the mean number of injections/year was 5.6.
The French wAMD patients enrolled in the LUMINOUS study were slightly older, had similar baseline VA, a greater proportion had PED, and a similar proportion had non-ocular comorbidities at baseline, compared to the global cohort. In both cohorts, prior ranibizumab treated patients had higher VA at baseline than treatment naïve patients. Future follow-up data from this cohort of French patients will provide an invaluable source of information from a diverse group of patients currently underrepresented in randomized clinical trials.
This PDF is available to Subscribers Only